Summary:
The main aim of this paper was to compare results of Genescan and real-time PCR methods in order to detect contamination in harvests from patients with follicular lymphoma. The secondary goal was to evaluate the efficacy of Rituximab as an in vivo purging agent. A total of 23 patients had been treated with CHOP followed by either high-dose therapy (12 patients) or high-dose plus Rituximab (11 patients), both followed by autologous transplantation. Results show that 86% of harvests from patients treated whith Rituximab were PCR-negative compared to 14.3% from controls. Real-time PCR was more sensitive than Genescan PCR; quantitative analysis revealed a correlation between the amount of contamination in the harvests and relapse after transplantation. Whereas all patients reinfused with negative aphereses achieved complete remission and showed a significantly better 5-year PFS (100%) compared to those reinfused with contaminated samples (41%), a very low amount of contamination does not appear to negatively affect outcome, suggesting that determination of a cutoff in the contamination level of harvests could be useful. Results suggest that real-time PCR is superior to Genescan PCR to select transplantable harvests and confirm the ability of Rituximab as an in vivo purging tool for follicular lymphoma.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Gribben JG, Freedman AS, Woo SD et al. All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of BCL2 have residual containing the BCL2 rearrangement at evaluation and after treatment. Blood 1991; 78: 3275–3280.
Freedman AS, Neuberg D, Mauch P et al. Long-term follow up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 1999; 94: 3325–3333.
Cleary ML, Sklar J . Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. Proc Natl Acad Sci USA 1985; 82: 7439–7443.
Corradini P, Astolfi M, Cherasco C et al. Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting. Blood 1997; 89: 724–731.
Gianni AM, Bregni M, Siena S et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997; 336: 1290–1297.
Mehra S, Messner H, Minden M, Chaganti RS . Molecular cytogenetic characterization of non-Hodgkin lymphoma cell lines. Genes Chromosomes Cancer 2002; 33: 225–234.
Ririe KM, Rasmussen RP, Wittwer CT . Product differentiation by analysis of DNA melting curves during the polymerase chain reaction. Analytical Biochemistry 1997; 245: 154–160.
Decaudin D, Lepage E, Brousse N et al. Low-grade follicular lymphoma: multivariate analysis of prognostic factors in 484 patients—a study of the Groupe d'etude des lymphomes de l'adulte. J Clin Oncol 1999; 17: 2499–2505.
Sacchi S, Federico M, Vitolo U et al. Clinical activity and safety of combination immunotherapy with interferon-α2a and rituximab in patients with relapsed low grade non-Hodgkin's lymphoma. Haematologica 2001; 86: 951–958.
Rambaldi A, Lazzari M, Manzoni C et al. Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood 2002; 99: 856–862.
Lazzarino M, Arcaini L, Bernasconi P et al. A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma. Br J Haematol 2002; 116: 229–235.
Hirt C, Dolken G . Quantitative detection of t(14;18)-positive cells in patients with follicular lymphoma before and after autologous bone marrow transplantation. Bone Marrow Transplant 2000; 25: 419–426.
Magni M, Di Nicola M, Devizzi L et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood 2000; 96: 864–869.
Moos M, Schulz R, Cremer F et al. Detection of minimal residual disease by polymerase chain reaction in B cell malignancies. Stem Cells 1995; 13 (Suppl 3): 42–51.
Acknowledgements
This paper is part of the molecular program of Italian Group for Lymphoma Study (GISL).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Galimberti, S., Guerrini, F., Morabito, F. et al. Quantitative molecular evaluation in autotransplant programs for follicular lymphoma: efficacy of in vivo purging by Rituximab. Bone Marrow Transplant 32, 57–63 (2003). https://doi.org/10.1038/sj.bmt.1704102
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1704102
Keywords
This article is cited by
-
Treatment of limited stage follicular lymphoma with Rituximab immunotherapy and involved field radiotherapy in a prospective multicenter Phase II trial-MIR trial
BMC Cancer (2011)
-
Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma
Bone Marrow Transplantation (2009)
-
Rituximab added to an intensified salvage chemotherapy program followed by autologous stem cell transplantation improved the outcome in relapsed and refractory aggressive non-Hodgkin lymphoma
Annals of Hematology (2006)
-
The role of rituximab in autologous and allogeneic hematopoietic stem cell transplantation for non-Hodgkin’s lymphoma
Current Hematologic Malignancy Reports (2006)
-
Investigational strategies in autologous stem cell transplantation for follicular lymphoma
Current Oncology Reports (2006)